



## Financial Tear Sheet

### Corporate Profile

Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, for the treatment of sickle cell disease and idiopathic pulmonary fibrosis.

### Primary IR Contact

Myesha Lacy

**Phone:** 650-351-4730

**E-mail:** [investor@gbt.com](mailto:investor@gbt.com)

### Stock Performance

#### GBT (Common Stock)

**Exchange** NASDAQ GS (US Dollar)

**Price** **\$44.60**

**Change (%)** ▲ 1.50 (3.48%)

**Volume** 694,598

**52 Week Low** \$24.03

**Market Cap** \$2,160,677,261

**Rolling EPS** -2.75

**PE Ratio** 0

**Shares Outstanding** 50,131,723

Data as of 04/25/18 4:00 p.m. ET



## Recent Headlines & Events

04/03/18

[GBT Announces Participation at the H.C. Wainwright  
Global Life Sciences Conference](#)

04/03/18

[GBT Announces New Employment Inducement Grants](#)

03/15/18

[GBT Announces New Employment Inducement Grants](#)

There are currently no events scheduled.

## SEC Filings

<b>Filing Date</b>	<b>Form</b>
04/19/18	<a href="#"><u>4</u></a>
03/20/18	<a href="#"><u>4</u></a>
03/14/18	<a href="#"><u>3</u></a>
03/12/18	<a href="#"><u>424B5</u></a>

## Corporate Governance

[Ted W. Love, M.D.](#) Chief Executive Officer

[Jeffrey Farrow](#) Chief Financial Officer

[Jung E. Choi](#) Chief Business and Strategy Officer

[Tricia Suvari](#) Chief Legal Officer

[Hing Sham, Ph.D.](#) Senior Vice President, Research

[Peter Radovich](#) Vice President, Program Leadership  
and Business Strategy

*Data provided by Nasdaq. Minimum 15 minutes delayed.*